Verdinexor: A Novel Oral Therapy for Canine Lympoma
Tue, Feb 28
|Madonna Inn
This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1.
Time & Location
Feb 28, 2023, 6:00 PM
Madonna Inn, Madonna Inn, San Luis Obispo, CA 93401, USA
About the Event
Speaker: Julie Kluxdal, DVM
Topic: "Verdinexor: A Novel Oral Therapy for Canine Lymphoma"
This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events.
Dinner Meeting
Madonna Inn Restaurant
100 Madonna Rd
San Luis Obispo, CA 93405
805-543-3000
Tuesday, February 28, 2023
Check-In: 6:00 PM - 6:30 PM, Pacific
Presentation: 6:30 PM - 7:30 PM, Pacific
Register by: Tuesday, February 21, 2023 by using the following link:
https://www.eventbrite.com/e/canine-lymphoma-23085-tickets-525723622507
CE Credits: 1
Contact:
Jamie Havard, Territory Manager
559-789-6820
Jamie.Havard@dechra.com
This is a private event for members of the MCVMA.